Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial
Publication
, Conference
Loomba, R; Guy, C; Bedossa, P; Taub, R; Bashir, M; Harrison, S
Published in: JOURNAL OF HEPATOLOGY
2020
Duke Scholars
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
2020
Volume
73
Start / End Page
S56 / S56
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Loomba, R., Guy, C., Bedossa, P., Taub, R., Bashir, M., & Harrison, S. (2020). Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial. In JOURNAL OF HEPATOLOGY (Vol. 73, pp. S56–S56).
Loomba, Rohit, Cynthia Guy, Pierre Bedossa, Rebecca Taub, Mustafa Bashir, and Stephen Harrison. “Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial.” In JOURNAL OF HEPATOLOGY, 73:S56–S56, 2020.
Loomba R, Guy C, Bedossa P, Taub R, Bashir M, Harrison S. Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial. In: JOURNAL OF HEPATOLOGY. 2020. p. S56–S56.
Loomba, Rohit, et al. “Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial.” JOURNAL OF HEPATOLOGY, vol. 73, 2020, pp. S56–S56.
Loomba R, Guy C, Bedossa P, Taub R, Bashir M, Harrison S. Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial. JOURNAL OF HEPATOLOGY. 2020. p. S56–S56.
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
2020
Volume
73
Start / End Page
S56 / S56
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences